Kyverna Therapeutics, Inc. Overview
Pro stress-test →Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syndrome, myasthenia gravis, lupus nephritis, multiple sclerosis, and systemic sclerosis. The company is pioneering a durable disease-clearing approach aiming for deep B cell depletion and an immune system reset to achieve treatment-free remission.
Strategic Profile
Pro stress-test →Kyverna has experienced leadership from Kite Therapeutics veterans with proven CAR-T market expertise. The company maintains ample funding with cash runway extending well into 2027 without additional fundraising. The company has a license and collaboration agreement with Intellia Therapeutics to develop an allogeneic CD19 CAR T-cell product.
Competitive Landscape
Pro stress-test →Kyverna is building presence in the biopharmaceutical landscape through innovative CAR T-cell technology, robust clinical strategy, and collaborative partnerships. Key competitors in CAR-T for autoimmune disease include Artiva Biotherapeutics, Cabaletta Bio, and other clinical-stage immunotherapy companies, though Kyverna appears positioned as a potential first-to-market for CAR-T in autoimmune indications.
Industry Context
Kyverna Therapeutics, Inc. operates in Biopharmaceuticals - Cell Therapy / Immunotherapy.
Key facts
Founded: 2018 · Headquarters: Emeryville, California · Revenue: $0 · Market cap: ~$93M